Results 71 to 80 of about 53,618 (254)
Health-related Quality of Life in Women with Polycystic Ovary Syndrome
Polycystic ovary syndrome is the most frequent endocrine and metabolic disorder in women of reproductive age. Its characteristic signs and symptoms are menstrual irregularities, amenorrhea, acne, hirsutism, obesity and infertility.
Belén Carazo Hernández +5 more
doaj +2 more sources
Objectives: The purpose of this scoping review is to explore research studies on the association between chronic pain and polycystic ovary syndrome to create local (U.S.-based) and global recommendations to improve access to and quality of affordable ...
Lea Sacca +7 more
doaj +1 more source
Treatment of adolescent girls with polycystic ovary syndrome and insulin resistance
Aim. Polycystic ovary syndrome is a common cause of infertility. In addition, polycystic ovary syndrome is often associated with metabolic complications. In most women hyperandrogenic manifestations occur during puberty.
E. M. Bogatyreva, G. A. Novik
doaj +1 more source
Epilepsy: Global Trends and the Chinese Experience (1990–2021). The infographic depicts (left) the global distribution of age‐standardized epilepsy DALY rates; (center) the triple inequality gap within China, including regional mortality disparities (9‐fold difference between western and eastern provinces), urban‐rural treatment gaps (60%–90%), and ...
Ting Chen +7 more
wiley +1 more source
Polycystic ovary syndrome is a common reproductive endocrine condition that affects women of fertile age and is characterized by three main features, including hyperandrogenism, chronic anovulation, and polycystic ovaries. In addition, half of women with
Salwa Bader +3 more
doaj +1 more source
Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Agents and Body Composition: Filling More Gaps
ABSTRACT The last 2 decades have seen historic advances in the treatment of obesity. We are entering an era of defining obesity not by weight‐based outcomes but by changes in body composition. Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are forming the platform for obesity treatments based on their high level of efficacy. Body composition can
Robert L. Dubin +4 more
wiley +1 more source
ABSTRACT Objective SURMOUNT‐REAL UK will evaluate the effectiveness of tirzepatide when offered in addition to standard‐of‐care (SoC) in adults with Class I obesity (BMI ≥ 30 and ≤ 34.9 kg/m2) and without diabetes in a UK primary care setting. Methods A 5‐year, phase 4, multicenter, open‐label, pragmatic randomized clinical trial is enabled through ...
Martin K. Rutter +14 more
wiley +1 more source
Utilizing network toxicology, molecular docking, and dynamic simulations to investigate the potential reproductive toxicity of bisphenol S (BPS). ABSTRACT The aim of this study was to investigate the potential reproductive toxicity of bisphenol S (BPS) and the related molecular mechanisms through a network toxicology approach.
Siyuan Wang +7 more
wiley +1 more source
Christine Brady, Shaymaa S Mousa, Shaker A MousaThe Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, NY, USAAbstract: In the past, polycystic ovary syndrome has been looked at primarily as an endocrine disorder ...
Christine Brady +2 more
doaj
Obesity and Polycystic Ovary Syndrome
The core pathophysiology of polycystic ovary syndrome involves an overproduction of androgens primarily originating from ovarian thecal cells. Two major external triggers promote androgen overproduction in the ovaries: the increased secretion of ...
Jin Ju Kim
doaj +1 more source

